References
- 1. McLaughlin JK, Lipworth L. Epidemiologic aspects of renal cell cancer. Semin Oncol 2000; 27: 115-23.
- 2. Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004; 22: 3316-22.
- 3. Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 2007; 89: 1794-1801.
- 4. Forbes GS, McLeod RA, Hattery RR. Radiographic manifestations of bone metastases from renal carcinoma. AJR Am J Roentgenol 1977; 129: 61-6.
- 5. Reidy JF. Osteoblastic metastases from a hypernephroma. Br J Radiol 1975; 48: 225-7.
- 6. Neugut AI, Casper ES, Godwin TA, Smith J. Osteoblastic metastases in renal cell carcinoma. Br J Radiol 1981; 54: 1002-4.
- 7. Liu PT, Conley CR, Callstrom MR. Sclerotic bone metastases from sarcomatoid renal cell carcinoma. Skeletal Radiol 1999; 28: 590.
- 8. Sneag DB, Krajewski KM, Howard S, Jagannathan JP, Star KV, Ramaiya N. Sclerotic osseous metastases from renal cell carcinoma. Skeletal Radiol 2012; 41: 1169-75.
- 9. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-76.
- 10. Shinagare AB, Fennessy FM, Ramaiya NH, Jagannathan JP, Taplin ME, van den Abbeele AD. Urothelial cancers of the upper urinary tract: metastatic pattern and its correlation with tumor histopathology and location. J Comput Assist Tomogr 2011; 35: 217-22.
- 11. Bhat S. Role of surgery in advanced/metastatic renal cell carcinoma. Indian J Urol 2010; 26: 167-76.
- 12. Toyoda Y, Shinohara N, Harabayashi T, Abe T, Akino T, Sazawa A et al. Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur Urol 2007; 52: 163-8.
- 13. Keegan KA, Schupp CW, Chamie K, Hellenthal NJ, Evans CP, Koppie TM. Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol 2012; 188: 391-7.
- 14. Rosenberg SA, Yang JC, White DE. Durability of complete response in patients with metastatic cancer treatment with high dose IL2 identification of the antigen mediating response. Ann Surg 1998; 229: 307-19.
- 15. Divgi CR, Uzzo RG, Gatsonis C, Bartz R, Treutner S, Yu JQ, et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol 2013; 31: 187-94.
- 16. Rajer M. Kidney cancer. Radiol Oncol 2007; 41: 64-71.